The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

All Eyes on PCS - Analysis of the Retinal Microvasculature in Patients With Post-COVID-19 Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05635552
Recruitment Status : Recruiting
First Posted : December 2, 2022
Last Update Posted : December 2, 2022
Sponsor:
Collaborator:
Ludwig-Maximilians - University of Munich
Information provided by (Responsible Party):
PD Dr. Christoph Schmaderer, Technical University of Munich

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The goal of this observational, prospective study is to in depth analyze the retinal microvasculature in patients with Post-COVID-19 Syndrome (PCS). The main questions it aims to answer is:

Do patients with PCS show a prolonged endothelial dysfunction when compared with fully COVID-19 recovered participants? Does symptom severity in PCS patients correlate with the extend of endothelial dysfunction? Do these changes correlate with improvement in symptoms in the prospective observation?


Condition or disease Intervention/treatment
Long Covid19 Post COVID-19 Condition Endothelial Dysfunction Diagnostic Test: Dynamic retinal vessel analysis (DVA) Diagnostic Test: Optical coherence tomography (OCT) Diagnostic Test: Biochemistry and immune phenotyping Diagnostic Test: Handgrip strength test Diagnostic Test: Questionnaires (Patient reported outcomes)

Detailed Description:
The investigators will recruit patients with PCS, fully COVID-19 recovered participants and COVID-19 infection naïve participants. After comprehensive clarification and given written informed consent, measurements will take place in the Klinikum rechts der Isar. To evaluate the retinal microvasculature dynamic retinal vessel analysis (DVA) and optical coherence tomography (OCT) are used. Patient reported outcomes (PROM) of PCS typical symptoms will be collected using standardized questionnaires. To ensure data quality the investigators will use standard operating procedures (SOP) for both technical measurements and data collection. For DVA measurements all examiners will be trained by a single experienced supervisor and must reach high image accuracy and quality in at least 10 volunteers. Examiners are only involved in data acquisition.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: All Eyes on PCS - Analysis of the Retinal Microvasculature in Patients With Post-COVID-19 Syndrome
Actual Study Start Date : October 17, 2022
Estimated Primary Completion Date : February 21, 2023
Estimated Study Completion Date : July 21, 2023

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
PCS patients
Patients with a COVID-19 infection at least 3 months ago (positive PCR or rapid antibody test) and PCS typical symptoms (e.g. fatigue, breast pain, heart palpitations, cognitive impairment) ongoing for at least 2 months and which cannot be explained by an alternative diagnosis.
 Diagnostic Test: Dynamic retinal vessel analysis (DVA)
DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.

Diagnostic Test: Optical coherence tomography (OCT)
OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.

Diagnostic Test: Biochemistry and immune phenotyping
Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.

Diagnostic Test: Handgrip strength test
Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.

Diagnostic Test: Questionnaires (Patient reported outcomes)
The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
COVID-19 recovered participants
Participants with Sars-CoV-2 infection at least 3 months ago (positive PCR or positive rapid antibody test) which are fully recovered.
 Diagnostic Test: Dynamic retinal vessel analysis (DVA)
DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.

Diagnostic Test: Optical coherence tomography (OCT)
OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.

Diagnostic Test: Biochemistry and immune phenotyping
Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.

Diagnostic Test: Handgrip strength test
Measure the maximum isometric strength of the hand and forearm muscles and their fatiguability.

Diagnostic Test: Questionnaires (Patient reported outcomes)
The questionnaires evaluate anxiety, depression, chronic fatigue, quality of life, and post-covid typical symptoms
COVID-19 infection naïve

No history of COVID-19 infection (exclusion via measurement of specific antibodies).

Consists of an already established, pre-pandemic healthy cohort and a cohort recruited during the pandemic.

 Diagnostic Test: Dynamic retinal vessel analysis (DVA)
DVA is an established, non-invasive tool to measure the responsiveness of retinal vessels to flickering light. In addition static retinal vessel parameters are recorded.

Diagnostic Test: Optical coherence tomography (OCT)
OCT is an imaging technique which applies low-coherence light to capture high resolution images from the ocular fundus.

Diagnostic Test: Biochemistry and immune phenotyping
Blood sample collection for clinical chemistry and isolation of PBMCs for FACS analysis.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. PCS patients show an impaired retinal vessel responsiveness when compared with fully recovered COVID-19 participants. [ Time Frame: Baseline ]
    Static and dynamic parameters of the retinal vessel analysis.


Secondary Outcome Measures :
  1. PCS patients show an impaired retinal vessel responsiveness at baseline when compared with infection naïve participants. [ Time Frame: Baseline ]
    Static and dynamic parameters of the retinal vessel analysis.

  2. PCS patients with improved symptoms show a change in retinal vessel responsiveness after 6 months when compared with baseline parameters. [ Time Frame: Baseline to month 6 ]
    Static and dynamic parameters of the retinal vessel analysis. Test items of the The COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) and PCS questionnaire. Calculation of PCS severity scores (Bahmer, 2022) in each patient with a range of score values from zero (better outcome) to 59 (worse outcome). Comparison of retinal vessel parameters and PCS scores between Baseline and month 6.

  3. Symptom severity of PCS in patients correlates with impaired retinal vessel responsiveness. [ Time Frame: Baseline ]
    Correlation between PCS severity scores with static and dynamic parameters of the retinal vessel analysis.

  4. PCS patients with impaired RVA analysis show elevated levels of markers of endothelial dysfunction and of chronic inflammation when compared with COVID-19 recovered cohort. [ Time Frame: Baseline ]

    Measurement of markers of endothelial dysfunction:

    Concentration of: sICAM, sVCAM, Thrombomodulin, P-Selectin,E-Selectin, ADMA, SADMA, Endothelin-1, ACE-1, ACE-2, ANG-2, GDF-15.

    Measurement of markers of chronic inflammation Concentration of IFN-β, IFN-λ1,TNFa. Comparison of marker levels to the COVID-19 recovered cohort.


  5. PCS patients with impaired RVA show a reactivation of EBV. [ Time Frame: Baseline ]
    Using PCR to measure EBV reactivation in patients plasma .

  6. Characterization of immune cell composition in PCS patients and comparison with COVID-19 recovered and COVID-19 infection naïve participants. [ Time Frame: Baseline ]
    Using flow cytometry to detect different T-cell and monocyte subpopulations.

  7. PCS patients show a decrease in vessel density in OCT-A when compared with COVID-19 recovered participants. [ Time Frame: Baseline ]
    Parameters of OCT-A.


Biospecimen Retention:   Samples With DNA
Blood and saliva samples are collected from the participants.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Community sample, Post-Covid ambulance, general practitioner
Criteria

Inclusion Criteria:

  • Patients with Post-COVID syndrome (positive PCR or positive rapid antibody test ≥3 months) with a currently existing, PCS-typical complaint complex, ongoing for at least 2 months and cannot be explained by an alternative diagnosis.
  • Control group: recovered from COVID-19 infection (positive PCR or positive rapid antibody test ≥ 3 months) without residual symptoms.
  • Healthy cohort: no history of COVID-19 infection

Exclusion Criteria:

  • Missing or incomplete consent form
  • Age < 18 years
  • Pregnancy
  • Malignancy
  • Diseases associated with a significant change in life expectancy
  • Autoimmune diseases of the rheumatological type
  • Cataract
  • Epilepsy
  • Glaucoma
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05635552


Contacts
Layout table for location contacts
Contact: Christoph Schmaderer, Prof. Dr. 089 4140 5053 christoph.schmaderer@mri.tum.de
Contact: Timon Kuchler 089 4140 8189 timon.kuchler@mri.tum.de

Locations
Layout table for location information
Germany
Klinikum rechts der Isar Recruiting
München, Bavaria, Germany, 81675
Contact: Christoph Schmaderer, Prof. Dr    089 4140 5053    christoph.schmaderer@mri.tum.de   
Contact: Timon Kuchler    089 4140 8189    timon.kuchler@mri.tum.de   
Principal Investigator: Christoph Schmaderer, Prof. Dr.         
Sub-Investigator: Timon Kuchler         
Sub-Investigator: Renate Hausinger         
Sub-Investigator: Matthias Braunisch, PD. Dr.         
Sub-Investigator: Roman Günthner, Dr.         
Sub-Investigator: Rebecca Wicklein, Dr.         
Sub-Investigator: Stanislas Werfel, Dr.         
Sub-Investigator: Andrea Ribero, Dr.         
Principal Investigator: Maciej Lech, Prof. Dr.         
Sponsors and Collaborators
Technical University of Munich
Ludwig-Maximilians - University of Munich
Investigators
Layout table for investigator information
Principal Investigator: Christoph Schmaderer, Prof. Dr. Technical University Munich
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: PD Dr. Christoph Schmaderer, Principal Investigator, Technical University of Munich
ClinicalTrials.gov Identifier: NCT05635552    
Other Study ID Numbers: 2022317PCS
First Posted: December 2, 2022    Key Record Dates
Last Update Posted: December 2, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by PD Dr. Christoph Schmaderer, Technical University of Munich:
Retinal Vessel Analysis
Retinal microvasculature
Autoimmunity
Inflammation
Vasculopathy
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Post-Acute COVID-19 Syndrome
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
 Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Post-Infectious Disorders
Chronic Disease
Disease Attributes
Pathologic Processes